US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist

1.250
+0.080+6.84%

Trading Jul 22 09:31 ET

319.45MMarket Cap-1721P/E (TTM)

Adaptimmune Therapeutics Stock Forum

Joy Boy Myth

Jul 11 06:08

If it goes right

Priority review $Adaptimmune Therapeutics(ADAP.US)$ within a month

TD Cowen Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating

Stock Region

Jun 2 14:36

Therapeutics Company Announces Major Clinical Collaboration Agreement

Clinical Collaboration Agreement Between Adaptimmune and Galapagos for Uza-cel TCR T-cell Therapy.
Adaptimmune Therapeutics plc, a company in T-cell therapies, and Galapagos NV, recognized for its innovative approaches to drug discovery and development, have announced a clinical collaboration agreement. This partnership focuses on the exclusive licensing option for Adaptimmune's TCR T-cell therapy candidate, uza-cel, specifical...

Abela

May 30 15:45

$Adaptimmune Therapeutics(ADAP.US)$ 100m upfront payment which is half of MC but ppl are not interested, so it looks good for shots to hit it hard🙏🙏🙏

Trytosaveabit

May 30 15:34

$Adaptimmune Therapeutics(ADAP.US)$ Here come the SS’s

70994532

May 30 15:12

$Adaptimmune Therapeutics(ADAP.US)$ It will fly to $2 tomorrow

Trytosaveabit

May 30 15:12

$Adaptimmune Therapeutics(ADAP.US)$ If you can break 1.45? I guess i will look for 1.57, 1.70? NFA Just thinking outloud

Trytosaveabit

May 30 15:03

News

$Adaptimmune Therapeutics(ADAP.US)$ Reg-Galapagos and Adaptimmune Sign Clinical Collaboration Agreement With an Option to Exclusively License Adaptimmune’s Tcr T-Cell Therapy Candidate, Uza-Cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications! To receive 100 million upfront payments

Trytosaveabit

May 15 06:17

Hmm

$Adaptimmune Therapeutics(ADAP.US)$ Adaptimmune Therapeutics PLC - Secures up to $125 Million Debt Financing With Hercules Capital

Trytosaveabit

Apr 12 07:14

Hmm?

$Adaptimmune Therapeutics(ADAP.US)$ Adaptimmune Therapeutics : on April 10, Unit of Co, Received Notice of Termination of Strategic Collaboration and License Agreement With Genentech

Sean Parker

Apr 5 17:26

Priority FDA Review

$Adaptimmune Therapeutics(ADAP.US)$Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review.
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade.
(Type of Cancer) Synovial Sarcoma : There are more than 50 different types of soft tissue sarcomas which are categorise...

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Overall